DE2458465A1 - Verfahren zur herstellung eines lyophilisierten normalen humanurins zur arzneimittelkontrolle - Google Patents
Verfahren zur herstellung eines lyophilisierten normalen humanurins zur arzneimittelkontrolleInfo
- Publication number
- DE2458465A1 DE2458465A1 DE19742458465 DE2458465A DE2458465A1 DE 2458465 A1 DE2458465 A1 DE 2458465A1 DE 19742458465 DE19742458465 DE 19742458465 DE 2458465 A DE2458465 A DE 2458465A DE 2458465 A1 DE2458465 A1 DE 2458465A1
- Authority
- DE
- Germany
- Prior art keywords
- urine
- resin
- comparison
- drugs
- xad
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims description 45
- 229940079593 drug Drugs 0.000 title claims description 44
- 238000000034 method Methods 0.000 title claims description 27
- 210000002700 urine Anatomy 0.000 claims description 137
- 229920005989 resin Polymers 0.000 claims description 46
- 239000011347 resin Substances 0.000 claims description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000004458 analytical method Methods 0.000 claims description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- 239000012153 distilled water Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000012216 screening Methods 0.000 claims description 6
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 claims description 5
- 229920006026 co-polymeric resin Polymers 0.000 claims description 5
- 239000002689 soil Substances 0.000 claims description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 28
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 24
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 19
- 229940025084 amphetamine Drugs 0.000 description 19
- 231100000027 toxicology Toxicity 0.000 description 18
- 239000011550 stock solution Substances 0.000 description 17
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 14
- 229940125717 barbiturate Drugs 0.000 description 14
- 229960005181 morphine Drugs 0.000 description 14
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 12
- 229960004126 codeine Drugs 0.000 description 12
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 12
- 229960001797 methadone Drugs 0.000 description 12
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 10
- 229930013930 alkaloid Natural products 0.000 description 10
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 10
- 229920001429 chelating resin Polymers 0.000 description 10
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 9
- 229960000482 pethidine Drugs 0.000 description 9
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 9
- 229960002695 phenobarbital Drugs 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 229960001252 methamphetamine Drugs 0.000 description 8
- 229960001301 amobarbital Drugs 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- KQPKPCNLIDLUMF-UHFFFAOYSA-N secobarbital Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O KQPKPCNLIDLUMF-UHFFFAOYSA-N 0.000 description 7
- 229960002060 secobarbital Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 150000003797 alkaloid derivatives Chemical class 0.000 description 6
- 229940126601 medicinal product Drugs 0.000 description 6
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 5
- 229960001948 caffeine Drugs 0.000 description 5
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000003456 ion exchange resin Substances 0.000 description 5
- 229920003303 ion-exchange polymer Polymers 0.000 description 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 4
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 229960002715 nicotine Drugs 0.000 description 4
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 239000004327 boric acid Substances 0.000 description 3
- 238000007877 drug screening Methods 0.000 description 3
- 238000001030 gas--liquid chromatography Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- BCXHDORHMMZBBZ-DORFAMGDSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;sulfuric acid Chemical compound OS(O)(=O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC BCXHDORHMMZBBZ-DORFAMGDSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 description 2
- 229940008238 amphetamine sulfate Drugs 0.000 description 2
- PYHRZPFZZDCOPH-UHFFFAOYSA-N amphetamine sulfate Chemical compound OS(O)(=O)=O.CC(N)CC1=CC=CC=C1.CC(N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229960003871 codeine sulfate Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229960002532 methamphetamine hydrochloride Drugs 0.000 description 2
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229960000948 quinine Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NBUHTTJGQKIBMR-UHFFFAOYSA-N 4,6-dimethylpyrimidin-5-amine Chemical compound CC1=NC=NC(C)=C1N NBUHTTJGQKIBMR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 101100016398 Danio rerio hars gene Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000444674 Narcotica Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940086789 amobarbital 50 mg Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 229940080861 demerol Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229950007554 levmetamfetamine Drugs 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940051129 meperidine hydrochloride Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960005189 methadone hydrochloride Drugs 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- -1 methaphetamine Chemical compound 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- IXRNQIKIVWWFBH-UHFFFAOYSA-N n-(1-phenylethenyl)acetamide Chemical compound CC(=O)NC(=C)C1=CC=CC=C1 IXRNQIKIVWWFBH-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- WCNLCIJMFAJCPX-UHFFFAOYSA-N pethidine hydrochloride Chemical compound Cl.C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 WCNLCIJMFAJCPX-UHFFFAOYSA-N 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940066471 secobarbital 50 mg Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/901—Drugs of abuse, e.g. narcotics, amphetamine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US428564A US3901655A (en) | 1973-12-26 | 1973-12-26 | Urine toxicology control |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2458465A1 true DE2458465A1 (de) | 1975-07-10 |
Family
ID=23699445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19742458465 Pending DE2458465A1 (de) | 1973-12-26 | 1974-12-10 | Verfahren zur herstellung eines lyophilisierten normalen humanurins zur arzneimittelkontrolle |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US3901655A (enExample) |
| JP (1) | JPS50117493A (enExample) |
| DE (1) | DE2458465A1 (enExample) |
| FR (1) | FR2256412A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4011045A (en) * | 1975-02-14 | 1977-03-08 | Bonderman Dean P | Turbidity reduction in triglyceride standards |
| US4020006A (en) * | 1975-08-14 | 1977-04-26 | Icl/Scientific | Fluid containing dispersed particles simulating leukocytes and method for producing same |
| JPS5241570A (en) * | 1975-09-29 | 1977-03-31 | Yokogawa Hokushin Electric Corp | Thermocouple thermometer |
| CA1076481A (en) * | 1976-05-24 | 1980-04-29 | Jen C. Hsia | Drug compositions |
| US4752448A (en) * | 1985-12-18 | 1988-06-21 | Keystone Diagnostics, Inc. | Drug abuse test paper |
| US5104622A (en) * | 1988-07-27 | 1992-04-14 | Bio-Rad Laboratories, Inc. | System for broad spectrum drug detection |
| US5057437A (en) * | 1988-07-27 | 1991-10-15 | Bio-Rad Laboratories, Inc. | Method for broad spectrum drug detection |
| US5352585A (en) * | 1993-06-29 | 1994-10-04 | Bio-Rad Laboratories, Inc. | System for benzodiazepine detection |
| US5955370A (en) * | 1993-11-02 | 1999-09-21 | U.D. Testing, Inc. | Urine adulteration test method |
| JP4389005B2 (ja) * | 1993-11-02 | 2009-12-24 | ユー．ディー．テスティング．インコーポレイテッド | 患者が薬剤処方に従っているかどうかをモニターする方法 |
| US5776783A (en) * | 1993-11-02 | 1998-07-07 | Private Clinic Laboratories, Inc. | Method of monitoring therapeutic agent consumption |
| US5547878A (en) * | 1993-11-02 | 1996-08-20 | Kell; Michael | Method of monitoring patient compliance with medications prescriptions |
| US6124136A (en) * | 1993-11-02 | 2000-09-26 | U. D. Testing, Inc. | Method of monitoring compliance with methadone treatment program |
| US5896692A (en) * | 1996-02-29 | 1999-04-27 | Collora; Samuel C. | Freeze dried scent lures |
| US6136801A (en) * | 1998-12-24 | 2000-10-24 | U. D. Testing, Inc. | Therapeutic agent with quantitative consumption marker |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3625652A (en) * | 1970-03-17 | 1971-12-07 | Marquette School Of Medicine I | Analysis of narcotics and amphetamines |
-
1973
- 1973-12-26 US US428564A patent/US3901655A/en not_active Expired - Lifetime
-
1974
- 1974-12-10 DE DE19742458465 patent/DE2458465A1/de active Pending
- 1974-12-20 FR FR7442312A patent/FR2256412A1/fr not_active Withdrawn
- 1974-12-26 JP JP49148553A patent/JPS50117493A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US3901655A (en) | 1975-08-26 |
| JPS50117493A (enExample) | 1975-09-13 |
| FR2256412A1 (enExample) | 1975-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2410033C2 (de) | Isolierung von in lipophilen Lösungsmitteln löslichen Inhaltstoffen wäßriger Lösungen | |
| DE2458465A1 (de) | Verfahren zur herstellung eines lyophilisierten normalen humanurins zur arzneimittelkontrolle | |
| DE2648458C2 (de) | Verfahren zum Nachweis eines im Serum von Krebspatienten vorkommenden, spezifischen Proteins und Reagenz zur Durchführung dieses Verfahrens | |
| EP2072054B1 (de) | Verwendung eines Extraktes aus Blättern von Ginkgo biloba | |
| DE68904922T2 (de) | Piroxicam in waessrigen loesungen enthaltende arzneizubereitungen und verfahren zu deren herstellung. | |
| DE112008003744T5 (de) | Fettemulsion, umfassend Ganoderma-Sporenöl, Verfahren zur Qualitätskontrolle und Verwendung davon | |
| DE60217351T2 (de) | Verfahren zur Proben-Identifizierung bei einem Säugetier sowie ein Kit zur Durchführung dieses Verfahrens | |
| EP0599307A1 (de) | Johanniskraut-Trockenextrakt, Verfahren zu seiner Herstellung und seine Verwendung | |
| DE112011102409T5 (de) | Verfahren zur Behandlung der Alzheimer-Krankheit | |
| CH647150A5 (de) | Zubereitung, enthaltend ein tranquillans und ein propiophenon. | |
| AT389226B (de) | Verfahren zur herstellung einer analgetischen und antiinflammatorischen pharmazeutischen zubereitung | |
| DE3421789C2 (enExample) | ||
| DE112011102411T5 (de) | Verfahren zur Behandlung von Aufmerksamkeits-Mangel-Hyperaktivitäts-Störung | |
| DE68922109T2 (de) | Gamma-inulin-zusammensetzungen. | |
| DE60201525T2 (de) | Verfahren zur herstellung eines an wirkstoffen hochangereicherten extraktes der blätter von ginkgo biloba | |
| LU86164A1 (de) | Verfahren zu herstellung von isosilybinfreiem silibinin und arzneimittel,enthaltend silibinin | |
| DD144719A5 (de) | Verfahren zur gewinnung einer natuerlichen polarfraktion mit antipsoriatischer wirksamkeit | |
| DE2745237A1 (de) | Mittel zur immunisierung und zum nachweis von speziellen krebsarten | |
| EP0307566A2 (de) | Verfahren zur kristallmorphologischen Blut- und Harnanalyse, zur Frühdiagnose und zur Herstellung von Arzneimitteln | |
| EP0014956A1 (de) | Mikrochromatographisches System für Urinproben zur Kontrolle der Arzneimitteleinnahme | |
| EP0234186B1 (de) | Verwendung von Oligopeptiden zur Behandlung von cerebralen Störungen | |
| DE3787971T2 (de) | Aktives prinzip, isoliert aus haigeweben. | |
| DE3689767T2 (de) | Immunverstärker und verwandte Zusammensetzungen. | |
| DE19603788B4 (de) | Wirkstoffextrakt aus Teufelskrallenwurzel, diesen enthaltendes human- oder veterinärmedizinisches Präparat, Verfahren zur Herstellung eines hochkonzentrierten Extraktes aus Radix Harpagophyti oder Herba und Radix Scrophularia sowie dessen Verwendung | |
| DE4110217A1 (de) | Verfahren zur herstellung von kristallisaten zur fruehdiagnose oder zur praevention von erkrankungen und zur herstellung von arzneimitteln |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHJ | Non-payment of the annual fee |